Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Tax Provision
Aquestive Therapeutics Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Tax Provision
$14k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Tax Provision
-$4.8B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Tax Provision
-$554m
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Tax Provision
$28m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Tax Provision
-$2.8B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Tax Provision
-$2.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-13%
|
|
Aquestive Therapeutics Inc
Glance View
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.
See Also
What is Aquestive Therapeutics Inc's Tax Provision?
Tax Provision
14k
USD
Based on the financial report for Dec 31, 2024, Aquestive Therapeutics Inc's Tax Provision amounts to 14k USD.
You don't have any saved screeners yet